FOR REFRACTORY GLAUCOMA

XEN® helps put the power to control her IOP in your hands

LEARN HOW

IOP = intraocular pressure.

THINK XEN® AT THE POINT OF YOUR SURGICAL DECISION.

The first ab interno approach to create a new pathway for aqueous outflow1

Demonstrated to reduce IOP for a broad range of refractory glaucoma patients1

Established efficacy and safety data1

DESIGNED FOR EFFICACY

XEN® Gel Stent is the only FDA-cleared stent that creates a low-lying, ab interno bleb for effective intraocular pressure (IOP) reduction.2

LEARN MORE

PATIENT SELECTION

XEN® Gel Stent is indicated for refractory glaucoma patients, including those who are1:

  • Pseudophakic
  • Uncontrolled on maximum tolerated medical therapy
  • Inadequately controlled by prior surgery, including MIGS and SLT*
  • Undergoing cataract surgery or a stand-alone procedure

*In the clinical study, prior surgery only included trabeculectomy, tube shunt, canaloplasty, selective laser trabeculoplasty (SLT), and trabeculotomy.

VIEW DETAILS

Pseudophakic (with or without prior MIGS)*

Inadequately controlled by prior surgery including MIGS*

Uncontrolled on maximum tolerated medical therapy

Undergoing cataract surgery (can be performed in combination with XEN® Gel Stent)

MIGS = minimally invasive glaucoma surgery.

DOCUMENTED XEN® GEL STENT OUTCOMES

In the primary analysis at 12 months, 76.3% (95% CI = 65.8, 86.8%) of subjects achieved ≥ 20% mean diurnal IOP reduction on the same or fewer number of medications vs baseline (N = 65).1

MORE DATA

PROVEN SAFETY DATA

Learn more about the proven safety data of XEN® Gel Stent through pivotal safety data and the 2-year APEX study. 

12-MONTH PIVOTAL STUDY SAFETY DATA
2-YEAR APEX SAFETY DATA

REQUEST UPDATES, RESOURCES, OR FOLLOW-UP

REQUEST NOW